FDA Brief

Warning letters Drugs

FDA warning letter to

Tyrone L. McCall, M.D./Cornea Associates of Texas

High riskIssued Mar 22, 2023Posted Mar 28, 2023Center for Drug Evaluation and Research | CDER

FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.

What happened

FDA inspected Cornea Associates of Texas, in Dallas, from September 12 to 19, 2022, reviewing its role as sponsor of two clinical investigations and Dr. McCall's role as sponsor representative and clinical investigator. FDA found the practice started and ran a study of a combination product of investigational drugs in 69 human subjects without submitting or having in effect an Investigational New Drug application (IND, the FDA permission needed before testing an unapproved drug in people).

What FDA found

  1. The sponsor began and ran a study of an unapproved drug combination in 69 people without first submitting and holding an IND.

    21 CFR 312.20(a), 312.20(b), 312.40(a)
  2. The product was not lawfully marketed in the United States, so the study did not qualify for an IND exemption.

    21 CFR 312.2
  3. The sponsor, not the IRB, is responsible for complying with IND rules.

    21 CFR part 312
  4. The company's written response was inadequate because it did not explain how it will decide when an IND is needed, how it will hold the planned pre-IND meeting, or what training staff will get.

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of the actions taken to prevent similar violations, or provide reasoning and supporting information if the company believes it complied.

Who should pay attention

  • physician practices acting as sponsors of their own studies
  • IRBs and research staff reviewing IND requirements
  • small sponsors running investigator-initiated drug trials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  2. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  3. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  4. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk